Human papillomavirus: recent developments in diagnosis and therapy

References

• BRANDSMA JL: Animal models for HPV vaccine develop-ment. In: Papillomavirus Reviews: Current Research on Papillomaviruses. C Lacey (Ed.), Leeds University Press (1996).
   Google Scholar
• MCBRIDE AA, ROMANCZUK H, PM HOWLEY: The papil-lomavirus E2 regulatory proteins. J. Biol. Chem. (1991) 266:18411–18414.
   PubMed Web of Science ®Google Scholar
• DE VILLIERS EM: Heterogeneity of the human papil-lomavirus group. J. Vim]: (1989) 63:4898–4903.
   Google Scholar
• FUCHS PG, PFISTER H: Papillomaviruises in Epider-modysplasia Verruciforrnis. In: Papillomavirus Reviews: Current Research on Papillomaldruses. C Lacey (Ed.), Leeds University Press (1996).
   Google Scholar
• FERENCZY A: Epidemiology and clinical pathophysiol-ogy of condylomata acuminata. Am. J. Obstet. Gynecol (1995) 172:1331–1339.
   PubMedGoogle Scholar
• PALEFSKY JM, EA HOLLY: Molecular virology and epidemiology of human papillomavirus and cervical cancer. Cancer Epidem. Biomarkers Prevention (1995) 4:415-428. A recent review of the histopathology of HPV-associated disease and the links between HPV, CIN and cervical cancer.
   Google Scholar
• LORINCZ AT, REID R, JENSON AB et al.: Human papil-lomavirus infection of the cervix: relative risk associa-tion of 15 common anogenital types. Obstet. Gynecol (1992) 79:328–327.
   PubMed Web of Science ®Google Scholar
• DANIEL B, RANGARAJAN A, MUKHERJEE G, VALLIKAD E, KRISHNA S: The link between integration and expres-sion of human papillomavirus type 16 genomes and cellular changes in the evolution of cervical intraepi-thelial neoplastic lesions. J. Gen. Virol. (1997) 78:1095–1101.
   PubMed Web of Science ®Google Scholar
• SOLINASTOLDO S, DURST M, LICHTER P: Specific chro-mosomal imbalances in human papillomavirus-trans-fected cells during progression toward immortality. PNAS (1997) 94:3854–3859.
   PubMedGoogle Scholar
• CONRAD-STOPPLER M, CHING MK, STOPPLER K et al.:Natural variants of the HPV-16 E6 protein differ in immortalizing activity and ability to degrade p53. J. Vim]. (1996) 70:6987–6993.
   Google Scholar
• ELLIS JRM, KEATING PJ, BAIRD J: The association of anHP V-16 oncogene variant with H1A-B7 has implications for vaccine design in cervical cancer. Nat. Med. (1995) 1:464–470.
   PubMedGoogle Scholar
• ELLIS JRM, ETHERINGTON I, GALLOWAY D, LUESLEY D,YOUNG LS: Antibody response to HPV-16 virus-like particles in women with cervical intraepithelial neo-plasia infected with a variant HPV-16. Lancet (1997) 349:1069–1070.
   Google Scholar
• KAYE JN, STARKEY WG, KELL B et al.: Human papil-lomavirus type 16 in infants: use of DNA sequence analyses to determine the source of infection. J. Gen. Vim]. (1996) 77:1139–1143.
   PubMed Web of Science ®Google Scholar
• REID R: Treatment of HPV-associated disease. In: Papil-lomavirus Reviews: Current Research on Papillomaviruses. C Lacey (Ed.), Leeds University Press (1996).
   Google Scholar
• SHERMAN ME, SCHIFFMAN MH: Toward objective qualityassurance in cervical cytopathology. Correlation of cytopathologic diagnosis and detection of high-risk human papillomavirus types. J.Clin. Pathol. (1994) 102:182–187.
   Google Scholar
• HARRY TC, SARAVANAMUTTA KM: Evaluation of the hybrid capture human papillomavirus deoxyribonu-cleic acid detection test. Am. J. Obstet. GynecoL (1997) 175:758–759.
   Google Scholar
• WIELAND U, PFISTER H: Molecular diagnosis of persist-ent human papillomavirus infections. Intervirology (1996) 39:145–157.
   PubMedGoogle Scholar
• KIRNBAUER R: Papillomavirus-like particles for serol-ogy and vaccine development. Intervirology (1996) 39:54–61.
   PubMed Web of Science ®Google Scholar
• STANLEY M: Genital human papillomaviruses - pros-pects for vaccination. CUIT. Opin. Infect. Dis. (1997) 10:55–61.
   Google Scholar
• PHELPS WC, ALEXANDER KA: Antiviral therapy for hu-man papillomavirus infection. Ann. Intern. Medicine (1995) 123:368–382.
   PubMed Web of Science ®Google Scholar
• KUBBUTAT MHG, VOUSDEN K: Role of E6 and E7 onco- proteins in HPV-induced anogenital malignancies. Semin. Virol. (1996) 7:295-304. A recent review of the role of the E6 and E7 oncoproteins in disrupting normal cell cycle control.
   Google Scholar
• COWSERT LM, FOX MC, ZON G, MIRABELLI CK: In vitroevaluation of phosphorothioate oligonucleotides tar-geted to the E2 mRMA of papillomavirus; potential treatment of genital warts. Antimicro b. Agents Chem other. (1993) 37:171–177.
   PubMed Web of Science ®Google Scholar
• POPA LM, SCHUTZH H, WINTER S, KITTLER L, LOBER G:Specific targetting of human papillomavirus type-16 E7 oncogene with triple-helix forming purine oligode-oxyribonucleotides. Biochem. Molec. Biol. (1996) 38:285–295.
   Google Scholar
• COLEMAN N, HUMPHRAY DL, BIRLEY A et al: Immu-nological events in regressing genital warts. Am. J. Clin. Pathol (1994) 102:768–774.
   PubMed Web of Science ®Google Scholar
• VERMUND SH, KELLEY KF, KLEIN RS et al.: High risk of human papillomavirus infection and cervical squarnous intra-epthelial lesions among women with symptomatic human immunodeficiency virus infec-tion. Am. J. Obstet. Gynecol (1991) 165:392–400.
   PubMed Web of Science ®Google Scholar
• BENTON EC, ARENDS MJ: Human papillomavirus in the immunocompromised. In: Papillomaidrus Reviews: Cur-rent Research on Papillomaidruses. C Lacey (Ed.), Leeds University Press (1996).
   Google Scholar
• FRAZER IH: Immunology of papillomavirus infection. Curr. Opin. Immunol (1996) 8:484-491. A review of the host immune response to viral early and late proteins, and host immune interactions with the papillomavirus virion.
   Google Scholar
• CHEN L, MIZUNO M, SINGHAL M et al Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing E6 oncoprotein of human papillomavirus type 16.1 Immunol. (1992) 148:2617–2621.
   PubMedGoogle Scholar
• CHEN L, THOMAS EK, HU SL, HELLSTROM I, HELLSTROM KE: Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc. Natl. Acad. Sci. USA (1991) 88:110–114.
   PubMed Web of Science ®Google Scholar
• TINDLE RW: Human papillomavirus vaccines for cervi- cal cancer. Curr. Opin. ImmunoL (1996) 8:643-650. A review on prophylactic and therapeutic papillomavirus vaccine candidates and the rationale supporting their use.
   Google Scholar
• SELVAKUMAR R, BORENSTEIN LA, UN YL, AHMED R,VVETTSTEIN FO: Immunization with non-structural pro-teins El and E2 of rabbit cottontail papillomavirus stimulates regression of virus induced papillomas../. Vi-rol. (1995) 69:602–605.
   PubMed Web of Science ®Google Scholar
• CAMPO MS: Vaccination against papillomavirus in cat-tle. Curr. Opin. Micro. Immunol (1994) 186:255–266.
   PubMedGoogle Scholar
• BREITBURD F, KIRNBAUER R, HUBBERT NL et al.: Immu- nisation with virus-like particles from cottontail rabbit papillomavirus (CREW) can protect against experimen-tal CRPV infection. J. Virol. (1995) 69:3959–3963.
   PubMed Web of Science ®Google Scholar
• CRISTENSEN ND, HOPFL R, DIANGELO SL et aL: Assembled baculovirus-expressed human papillomavirus type 11 capsid protein VLPs are recognised by neutralising antibody using mouse monoclonal antibody and induce high titres of neutralising antibody. J. Gen. Virol. (1994) 75:2271–2276.
   PubMedGoogle Scholar
• DONNELLY JJ, MARTINEX D, JANSEN KU et al: Protection against pap illomavirus with a polynucleotide vaccine J. Infect. Dis. (1996) 713:314-320. Direct injection of plasmid constructs encoding Li and L2 protects rabbits against challenge with CRPV.
   Google Scholar
• WU T-C, LEE BP, PARDOLL DM: Novel strategy to enhance immunogenicity of antigen. 15th International Papil-lomavirus Workshop, Brisbane, Australia, Abstr. 31 1 (1996).
   Google Scholar
• LEE BP, KURMAN RJ, PARDOLL M, WU T-C: Recombinantchimeric E7-LAMP-1 vaccinia prevents the growth of E6+/E7+ malignant tumors regardless of MHC back-ground. 15th International Papillomavirus Workshop (1996), Brisbane, Australia, Abstr. 288 (1996).
   Google Scholar
• RESSING ME, SELTE A, BRANDT RMP et al.: Human CTLepitopes encoded by human pap illomavirus type 16 E6 and E7 identified through in vivo and in vitro immuno-genicity studies of HLA-A*0201-binding peptides. J. Im-munol (1995) 154:5934–5943.
   PubMed Web of Science ®Google Scholar
• VAN DRIEL WJ, RESSING ME, BRANDT RM et al.: The current status of therapeutic HPV vaccine. Ann. Med. (1996) 28:471–477.
   PubMed Web of Science ®Google Scholar
• BORYSIEWICZ LK, FIANDER A, NIMAKO Metal: A recom-binant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet (1997) 347:1523–1527.
   Google Scholar
• KIRNBAUER R, CHANDRACHUD LM, O'NEIL BW et al: Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology (1996) 219:37–44.
   PubMed Web of Science ®Google Scholar
• HASSETT DE, WHITTON JL: DNA immunization. TrendsNlicrobiol (1996) 4:307–312.
   Google Scholar
• SUNDARAM P, TIGELAAR RE, BRANDSMA JL: Intracutane- ous vaccination of rabbits with the cottontail rabbitpapillomavirus (CRPV) L 1 gene protects against virus challenge. Vaccine (1997) 15:664-671. Use of jet injector delivery system to deliver gold particles coated with plasmid DNA encoding CRPV Li gene protects rabbits against challenge with CRPV virus.
   Google Scholar